檢索結果 - Moore, Kathleen N

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer 由 Moore, Kathleen N., Monk, Bradley J.

獲取全文 獲取全文 獲取全文

Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations 由 Moore, Kathleen N., Birrer, Michael J.

獲取全文 獲取全文 獲取全文

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? 由 Birrer, Michael J., Betella, Ilaria, Martin, Lainie P., Moore, Kathleen N.

獲取全文 獲取全文 獲取全文

Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2 由 Bishop, Erin A., Java, James J., Moore, Kathleen N., Walker, Joan L.

獲取全文 獲取全文 獲取全文

Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers 由 Kunos, Charles A., Andrews, Stephen J., Moore, Kathleen N., Chon, Hye Sook, Ivy, S. Percy

獲取全文 獲取全文 獲取全文

COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA 由 WOLFORD, JULIET E., BAI, JIARU, MOORE, KATHLEEN N., KRISTELEIT, REBECCA, MONK, BRADLEY J., TEWARI, KRISHNANSU S.

獲取全文 獲取全文 獲取全文

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion 由 Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle

獲取全文 獲取全文 獲取全文

Suppressed expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma 由 Zakharov, Vladislav, Lin, Hsueh-Kung, Azzarello, Joseph, McMeekin, Scott, Moore, Kathleen N, Penning, Trevor M, Fung, Kar-Ming

獲取全文 獲取全文

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders 由 Grisham, Rachel N., Moore, Kathleen N., Gordon, Michael S., Harb, Wael, Cody, Gwendolyn, Halpenny, Darragh F., Makker, Vicky, Aghajanian, Carol A.

獲取全文 獲取全文 獲取全文

Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary... 由 Coward, Jermaine I., Barve, Minal A., Kichenadasse, Ganessan, Moore, Kathleen N., Harnett, Paul R., Berg, Daniel, Garner, James S., Dizon, Don S.

獲取全文 獲取全文 獲取全文

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours 由 Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R

獲取全文 獲取全文 獲取全文

PROSPECTIVE EVALUATION OF MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER RISK INDEX SCORE FOR GYNECOLOGIC ONCOLOGY PATIENTS WITH FEBRILE NEUTROPENIA 由 Gunderson, Camille C., Erickson, Britt. K., Wilkinson-Ryan, Ivy, Vesely, Sara K., Leath, Charles A., Gehrig, Paola A., Moore, Kathleen N.

獲取全文 獲取全文 獲取全文

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors 由 Bendell, Johanna C., Patel, Manish R., Moore, Kathleen N., Chua, Cynthia C., Arkenau, Hendrik‐Tobias, Dukart, Gary, Harrow, Kim, Liang, Chris

獲取全文 獲取全文 獲取全文

A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration 由 Tan, Maxine, Li, Zheng, Qiu, Yuchen, McMeekin, Scott D., Thai, Theresa C., Ding, Kai, Moore, Kathleen N., Liu, Hong, Zheng, Bin

獲取全文 獲取全文 獲取全文

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors 由 Shah, Manisha H., Lorigan, Paul, O’Brien, Mary E. R., Fossella, Frank V., Moore, Kathleen N., Bhatia, Shailender, Kirby, Maurice, Woll, Penella J.

獲取全文 獲取全文 獲取全文

First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors 由 Moore, Kathleen N., Bendell, Johanna C., LoRusso, Patricia M., Olszanski, Anthony J., Zwick-Wallasch, Esther, Jansen, Mendel, Vandell, Alexander G., Senaldi, Giorgio

獲取全文 獲取全文 獲取全文

A phase I–II evaluation of veliparib (NSC#737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: An NRG On... 由 Kunos, Charles, Deng, Wei, Dawson, Dawn, Lea, Jayanthi S., Zanotti, Kristine M., Gray, Heidi J., Bender, David P., Guaglianone, Perry P., Carter, Jori S., Moore, Kathleen N.

獲取全文 獲取全文 獲取全文

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer 由 Gordhandas, Sushmita B., Manning-Geist, Beryl, Henson, Christina, Iyer, Gopa, Gardner, Ginger J., Sonoda, Yukio, Moore, Kathleen N., Aghajanian, Carol, Chui, M. Herman, Grisham, Rachel N.

獲取全文 獲取全文 獲取全文

A Phase I Evaluation of Extended Field Radiation Therapy with Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinom... 由 Boardman, Cecelia H, Brady, William E, Dizon, Don S, Kunos, Charles A, Moore, Kathleen N, Zanotti, Kristine M, Matthews, Cara, Cosin, Jonathan A, Aghajanian, Carol, Fracasso, Paula M

獲取全文 獲取全文 獲取全文

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Per... 由 Moore, Kathleen N., Martin, Lainie P., O’Malley, David M., Matulonis, Ursula A., Konner, Jason A., Perez, Raymond P., Bauer, Todd M., Ruiz-Soto, Rodrigo, Birrer, Michael J.

獲取全文 獲取全文 獲取全文